Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 318

2.

Cardiovascular thromboembolic events associated with febuxostat: investigation of cases from the FDA adverse event reporting system database.

Gandhi PK, Gentry WM, Bottorff MB.

Semin Arthritis Rheum. 2013 Jun;42(6):562-6. doi: 10.1016/j.semarthrit.2012.11.002. Epub 2013 Jan 24.

PMID:
23352248
3.

Escalating doses of C1 esterase inhibitor (CINRYZE) for prophylaxis in patients with hereditary angioedema.

Bernstein JA, Manning ME, Li H, White MV, Baker J, Lumry WR, Davis-Lorton MA, Jacobson KW, Gower RG, Broom C, Fitts D, Schranz J.

J Allergy Clin Immunol Pract. 2014 Jan-Feb;2(1):77-84. doi: 10.1016/j.jaip.2013.09.008. Epub 2013 Nov 11.

PMID:
24565773
4.

Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks.

Craig TJ, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz D, Obtułowicz K, Reshef A, Ritchie B, Moldovan D, Shirov T, Grivcheva-Panovska V, Kiessling PC, Keinecke HO, Bernstein JA.

J Allergy Clin Immunol. 2009 Oct;124(4):801-8. doi: 10.1016/j.jaci.2009.07.017. Epub 2009 Sep 19.

PMID:
19767078
5.

Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: an open-label trial.

Riedl MA, Hurewitz DS, Levy R, Busse PJ, Fitts D, Kalfus I.

Ann Allergy Asthma Immunol. 2012 Jan;108(1):49-53. doi: 10.1016/j.anai.2011.10.017. Epub 2011 Nov 21.

PMID:
22192966
6.

Icatibant. Attacks of hereditary angioedema: continue to use C1 esterase inhibitor.

[No authors listed]

Prescrire Int. 2010 Nov;19(110):245-7. Review.

PMID:
21284353
7.

Potential for linezolid-related blindness: a review of spontaneous adverse event reports.

Brown J, Aitken SL, van Manen RP.

Pharmacotherapy. 2011 Jun;31(6):585-90. doi: 10.1592/phco.31.6.585.

PMID:
21923442
8.

Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).

DuMouchel W, Fram D, Yang X, Mahmoud RA, Grogg AL, Engelhart L, Ramaswamy K.

Ann Clin Psychiatry. 2008 Jan-Mar;20(1):21-31. doi: 10.1080/10401230701844612.

PMID:
18297583
9.

Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS.

Kadoyama K, Kuwahara A, Yamamori M, Brown JB, Sakaeda T, Okuno Y.

J Exp Clin Cancer Res. 2011 Oct 5;30:93. doi: 10.1186/1756-9966-30-93.

10.

Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.

Roberto G, Piccinni C, D'Alessandro R, Poluzzi E.

Cephalalgia. 2014 Jan;34(1):5-13. doi: 10.1177/0333102413499649. Epub 2013 Aug 6.

PMID:
23921799
11.

Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis.

Baker RA, Pikalov A, Tran QV, Kremenets T, Arani RB, Doraiswamy PM.

Psychopharmacol Bull. 2009;42(1):11-31.

PMID:
19204649
12.

Current medical management of hereditary angioedema: results from a large survey of US physicians.

Riedl M, Gower RG, Chrvala CA.

Ann Allergy Asthma Immunol. 2011 Apr;106(4):316-322.e4. doi: 10.1016/j.anai.2010.12.012. Epub 2011 Feb 5.

PMID:
21457880
13.

C1-esterase inhibitor transfusions in patients with hereditary angioedema.

Visentin DE, Yang WH, Karsh J.

Ann Allergy Asthma Immunol. 1998 Jun;80(6):457-61.

PMID:
9647267
14.

Three new drugs for hereditary angioedema.

[No authors listed]

Med Lett Drugs Ther. 2010 Aug 23;52(1345):66-7. No abstract available.

PMID:
20724964
16.
17.

Progress in the emergency management of hereditary angioedema: focus on new treatment options in the United States.

Bernstein JA, Moellman JJ.

Postgrad Med. 2012 May;124(3):91-100. doi: 10.3810/pgm.2012.05.2552. Review.

PMID:
22691903
18.

Adjunctive topiramate enhances the risk of hypothermia associated with valproic acid therapy.

Knudsen JF, Sokol GH, Flowers CM.

J Clin Pharm Ther. 2008 Oct;33(5):513-9. doi: 10.1111/j.1365-2710.2008.00943.x.

PMID:
18834366
19.

Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacks.

Li HH, Moldovan D, Bernstein JA, Reshef A, Porebski G, Stobiecki M, Baker J, Levy R, Relan A, Riedl M.

J Allergy Clin Immunol Pract. 2015 May-Jun;3(3):417-23. doi: 10.1016/j.jaip.2014.12.013. Epub 2015 Feb 11.

20.

Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study.

Moldovan D, Reshef A, Fabiani J, Kivity S, Toubi E, Shlesinger M, Triggiani M, Montinaro V, Cillari E, Realdi G, Cancian M, Visscher S, Zanichelli A, Relan A, Cicardi M.

Clin Exp Allergy. 2012 Jun;42(6):929-35. doi: 10.1111/j.1365-2222.2012.03984.x.

PMID:
22909164

Supplemental Content

Support Center